Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biodesix, Inc. stock logo
BDSX
Biodesix
$0.34
-3.7%
$0.53
$0.17
$2.04
$50.21M1.182.28 million shs3.72 million shs
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
$1.37
+16.1%
$0.00
$1.18
$6.50
$25.28MN/A899,796 shs1.53 million shs
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
$1.66
+3.8%
$1.75
$1.03
$2.55
$12.46M77.73540,223 shs14,010 shs
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
$7.19
-8.8%
$5.60
$3.80
$26.70
$31.22M-0.8426,055 shs24,925 shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biodesix, Inc. stock logo
BDSX
Biodesix
-3.74%+13.75%-30.82%-61.16%-77.46%
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
+16.10%-42.19%-68.86%+136,999,900.00%+136,999,900.00%
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
+4.08%+3.11%-4.05%-7.52%+23.88%
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
-10.01%-16.23%+51.82%+55.26%+40.75%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Biodesix, Inc. stock logo
BDSX
Biodesix
3.2703 of 5 stars
4.43.00.00.02.02.50.6
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
N/AN/AN/AN/AN/AN/AN/AN/A
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
3.3021 of 5 stars
3.55.00.00.00.73.31.3
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biodesix, Inc. stock logo
BDSX
Biodesix
2.80
Moderate Buy$1.75410.80% Upside
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
0.00
N/AN/AN/A
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
3.00
Buy$18.00984.34% Upside
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest BRTX, BDSX, CCM, and BMGL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/21/2025
Biodesix, Inc. stock logo
BDSX
Biodesix
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Outperform ➝ Sector Outperform$3.00 ➝ $2.00
5/14/2025
Biodesix, Inc. stock logo
BDSX
Biodesix
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$3.00 ➝ $2.00
5/14/2025
Biodesix, Inc. stock logo
BDSX
Biodesix
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$3.00 ➝ $1.50
5/14/2025
Biodesix, Inc. stock logo
BDSX
Biodesix
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$2.50 ➝ $1.50
5/14/2025
Biodesix, Inc. stock logo
BDSX
Biodesix
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform
4/29/2025
Biodesix, Inc. stock logo
BDSX
Biodesix
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$3.50 ➝ $2.50
3/4/2025
Biodesix, Inc. stock logo
BDSX
Biodesix
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biodesix, Inc. stock logo
BDSX
Biodesix
$71.32M0.70N/AN/A$0.05 per share6.85
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
$10.05M2.52N/AN/AN/A
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
$391K31.86N/AN/A$2.45 per share0.68
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
$383.96M0.08N/AN/A$56.67 per share0.13
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biodesix, Inc. stock logo
BDSX
Biodesix
-$52.15M-$0.29N/AN/AN/A-66.84%-275.79%-43.05%8/6/2025 (Estimated)
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
N/AN/A0.00N/AN/AN/AN/AN/A
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
-$14.41M-$1.47N/AN/AN/A-2,697.08%-98.49%-75.23%8/12/2025 (Estimated)
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
-$41.93MN/A0.00N/AN/AN/AN/AN/A

Latest BRTX, BDSX, CCM, and BMGL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
-$0.32-$0.56-$0.24-$0.64$0.38 million$0.03 million
5/13/2025Q1 2025
Biodesix, Inc. stock logo
BDSX
Biodesix
-$0.08-$0.08N/A-$0.08$19.50 million$17.96 million
3/27/2025Q4 2024
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
-$0.27-$0.20+$0.07-$0.20$0.48 million$0.50 million
3/3/2025Q4 2024
Biodesix, Inc. stock logo
BDSX
Biodesix
-$0.07-$0.06+$0.01-$0.06$19.92 million$20.43 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Biodesix, Inc. stock logo
BDSX
Biodesix
N/AN/AN/AN/AN/A
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
N/AN/AN/AN/AN/A
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
N/AN/AN/AN/AN/A
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biodesix, Inc. stock logo
BDSX
Biodesix
1.30
3.40
3.40
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
N/AN/AN/A
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
N/A
2.95
2.95
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
1.15
0.47
0.46

Institutional Ownership

CompanyInstitutional Ownership
Biodesix, Inc. stock logo
BDSX
Biodesix
20.96%
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
N/A
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
69.38%
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
N/A

Insider Ownership

CompanyInsider Ownership
Biodesix, Inc. stock logo
BDSX
Biodesix
69.20%
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
N/A
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
25.50%
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
46.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Biodesix, Inc. stock logo
BDSX
Biodesix
220146.56 million44.80 millionOptionable
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
3618.46 millionN/AN/A
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
77.51 million5.16 millionNot Optionable
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
9704.34 million2.32 millionNot Optionable

Recent News About These Companies

Concord Medical Services Holdings Ltd ADR
Concord Medical trading resumes
Learn to Evaluate (CCM) using the Charts
How the (CCM) price action is used to our Advantage
Concord Medical trading halted, volatility trading pause
(CCM) Long Term Investment Analysis
(CCM) On The My Stocks Page

New MarketBeat Followers Over Time

Media Sentiment Over Time

Biodesix stock logo

Biodesix NASDAQ:BDSX

$0.34 -0.01 (-3.74%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$0.35 +0.01 (+1.58%)
As of 05/23/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.

Basel Medical Group stock logo

Basel Medical Group NASDAQ:BMGL

$1.37 +0.19 (+16.10%)
As of 05/23/2025 04:00 PM Eastern

OUR MISSION Basel Medical transcends the role of a conventional healthcare provider. We strive for excellence in medical services and aim to serve as a beacon of hope for patients across Singapore and Southeast Asia. Our mission encompasses the four following commitments: Patient–Centered Care. We prioritize our patient’s wellbeing above all else. Innovation. We strive for excellence through innovation and expertise. Global Accessibility. We believe that quality healthcare should be universally available. Continuous Improvement. We constantly improve our services to meet evolving patient needs. With over 20 years of medical services experience, Basel Medical’s journey began with a simple commitment – to restore healthy and active lifestyles, one at a time. Today, that commitment has transformed into a vision for innovation, growth and far-reaching impact. We rely on an experienced group of medical practitioners to provide a wide spectrum of general and subspecialized orthopedic, trauma, sports medicine and neurosurgical services such as knee/hip replacements, sports medicine/surgery, spine surgery, foot/ankle surgery, minimally invasive orthopedic procedures and other complex neurosurgical procedures. We operate our two clinics at Gleneagles Medical Centre in Singapore and currently have five medical practitioners practicing with Basel Medical (together with its subsidiaries, the “Group”), comprising four orthopedic specialists and one neurosurgery specialist. The services provided by our clinics include, but are not limited to, consultation, medical diagnosis and medical or surgical treatments for orthopedic, trauma, sports medicine and neurological conditions and our clinics are equipped with the facilities needed to perform a variety of procedures on site and minor surgical services, while more complex surgical procedures are performed at operating theaters of other hospitals with such facilities. Our Group has a patient-oriented philosophy of providing personalized, quality and integrated medical care. We aim to be a one-stop integrated healthcare provider for all musculoskeletal-related medical care, including post-surgery rehabilitation services such as physiotherapy as well as other ancillary services such as pain management. Within the next 12 to 18 months, we intend to actively seek acquisition and collaboration partners in Singapore and Malaysia. Our acquisition and collaboration targets include general practitioner (GP) clinics and specialist clinics that complement our orthopedic services, particularly those focused on the musculoskeletal system, aging treatments, physiotherapy and occupational therapists. Our goal is to become an internationally known medical services provider in the Southeast Asian market, with a presence in at least four Southeast Asia countries (potentially covering Singapore, Malaysia, Indonesia and Thailand) within the next three years. As of the date of this prospectus, we have not identified such targets. Basel Medical was incorporated in the BVI on August 10, 2023 with registered number 2129740 as a BVI business company with liability limited by shares. Our BVI registered office is located at Kingston Chambers, PO Box 173, Road Town, Tortola, British Virgin Islands VG1110. Our principal executive offices are located in Singapore at 6 Napier Road, Unit #02-10/11 Gleneagles Medical Centre, Singapore. Our agent for service of process in the United States is Puglisi & Associates at 850 Library Avenue, Suite 204, Newark, Delaware.

BioRestorative Therapies stock logo

BioRestorative Therapies NASDAQ:BRTX

$1.66 +0.06 (+3.75%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$1.65 -0.01 (-0.36%)
As of 05/23/2025 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.

Concord Medical Services stock logo

Concord Medical Services NYSE:CCM

$7.19 -0.69 (-8.76%)
Closing price 05/23/2025 03:55 PM Eastern
Extended Trading
$7.08 -0.11 (-1.46%)
As of 05/23/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. It operates in two segments, Network and Hospital. The company's services include linear accelerators and external beam radiotherapy, proton therapy system, gamma knife radiosurgery, and diagnostic imaging services. Its other treatments and diagnostic services comprise positron emission tomography-computed tomography and magnetic resonance imaging scanners. In addition, the company provides clinical support services, such as developing treatment protocols for doctors, and organizing joint diagnosis between doctors in its network and clinical research, as well as helps to recruit and determine the compensation of doctors and other medical personnel. Further, it offers radiotherapy and diagnostic equipment leasing, management services, and premium cancer and proton treatment services to hospitals, as well as teleconsultation and medical information technology services; and sells medical equipment. Additionally, the company operates specialty cancer hospitals, which offers radiation, imaging, test laboratory, inpatient, and nursing services. Concord Medical Services Holdings Limited was founded in 1997 and is headquartered in Beijing, the People's Republic of China.